Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

Innovation in This Emerging Field Is Largely Driven by Smaller Firms, Specifically Start-Ups - Research and Markets

DUBLIN, October 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030" report to their offering.

The Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030 offers a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of products in the therapeutic vaccines segment of the immuno-oncology domain.

Currently, there are five types of such vaccines; these are dendritic cell vaccines, tumor cell vaccines, antigen / peptide vaccines, DNA vaccines and anti-idiotypic vaccines. This report is focused on the recent developments and the future potential of dendritic cell vaccines (dendritic cell loaded vaccines) and tumor cell vaccines (tumor cell loaded vaccines).

During the course of our study, we identified a variety of dendritic cell and tumor cell cancer vaccines across various stages of development. More than 75% of these product candidates are currently in the clinical stages of development. With a rich development pipeline, this segment of the immunotherapy market has managed to capture the interest of several strategic investors and venture capital firms.

USD 1.5 billion has already been invested in this domain in past five years. Owing to the existing unmet demand for safe and effective cancer therapies and given the innate advantages of immunotherapies, we believe that dendritic cell and tumor cell cancer vaccines present lucrative opportunities for both therapy developers and investors alike.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market.

For this purpose, we took into consideration the following parameters:

- The dendritic cell and tumor cell vaccines pipeline, including marketed, clinical and preclinical therapies, in terms of phase of development, key players, type of donor and target indications.
- The existing and emerging technology platforms used for the development of innovative variants of cancer vaccines.
- The partnerships that have taken place in the recent past covering clinical trial collaborations, research collaborations, manufacturing and services agreements, license agreements specific to technology platforms and agreements related to the co-development and co-commercialization of promising candidates.